AbhinavDeolMD

Oncology • Detroit, MI

Hematologic Oncology

Hematology/Oncology/ BMT, Karmanos Cancer Institute. Professor, Department of Oncology, Wayne State University

Join to view full profile

Dr. Deol is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Deol's full profile

Already have an account?

Office
4100 John R St
Detroit, MI 48201
Phone+1 800-527-6266

Fax+1 313-576-8767

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
Wayne State University School of MedicineResidency, Internal Medicine, 2004 - 2007
Government Medical College AmritsarClass of 2000

Certifications & Licensure

MI State Medical License 2004 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Start of enrollment: 2007 Jan 01
No longer available
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer Start of enrollment: 2010 Mar 08
Terminated
Phase 2
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery Start of enrollment: 2010 Jul 01
Terminated
Phase 2
Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL Start of enrollment: 2019 Mar 11
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2018 Jun 07
Completed
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

3371 citations
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos
The New England Journal of Medicine. 2017-12-10
1271 citations
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis
The Lancet. Oncology. 2019-01-01
53 citations
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
Yucai Wang, Preetesh Jain, Frederick L Locke, Matthew J Maurer, Matthew J Frank
Journal of Clinical Oncology. 2023-05-10

Abstracts/Posters

Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Abhinav Deol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Maintenance Therapy after Second Autologous Stem Cell Transplant in Multiple Myeloma Improves Overall Survival
Abhinav Deol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...
Abhinav Deol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Use of Thymoglobulin with Lower Dose of Busulfan Results in Less Acute Gvhd Following Unrelated Donor Allogeneic Stem Cell Transplantation for AML without Affecting Re...
Abhinav Deol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Abhinav Deol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Absolute Lymphocyte Count (ALC) Less Than 100 Predicts Adverse Transplant Outcomes with Rabbit Thymoglobulin in Patients Undergoing Matched Unrelated Allogeneic Hemato...
Abhinav Deol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 DataClinically Relevant Abs...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018